A PROPENSITY SCORE-BASED COMPARISON OF TEPOTINIB VERSUS IMMUNOTHERAPY WITH/WITHOUT CHEMOTHERAPY, USING REAL-WORLD DATA IN PREVIOUSLY UNTREATED MET EXON 14 (METEX14) SKIPPING NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Hook, E. [1 ]
Batteson, R. [2 ]
Christopoulos, P. [3 ,4 ,5 ]
Guisier, F. [6 ,7 ]
Ekman, S. [8 ]
Hatswell, A.
Vioix, H. [9 ]
机构：
[1] Delta Hat Ltd, Nottingham, NGM, England
[2] Delta Hat Ltd, Nottingham, England
[3] Heidelberg Univ Hosp, Thoraxklin, Heidelberg, Germany
[4] Heidelberg Univ Hosp, Natl Ctr Tumor Dis, Heidelberg, Germany
[5] German Ctr Lung Res DZL, Translat Lung Res Ctr Heidelberg TLRC H, Heidelberg, Germany
[6] Univ Rouen Normandie, Dept Pneumol, LITIS Lab QuantIF team EA4108, CHU Rouen, F-76000 Rouen, France
[7] Inserm CIC CRB 1404, F-76000 Rouen, France
[8] Karolinska Univ Hospital, Dept Oncol Pathol, Karolinska Inst, Stockholm, Sweden
[9] Merck Healthcare KGaA, Darmstadt, Germany
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
CO168
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [31] Tepotinib in patients with advanced non-small lung cancer (NSCLC) and MET exon 14-skipping mutations: Phase II data
    Sakai, H.
    Felip, E.
    Cortot, A. B.
    Veillon, R.
    Griesinger, F.
    Patel, J.
    Horn, L.
    Mazieres, J.
    De Castro Carpeno, J.
    Morise, M.
    Sakamoto, T.
    Bruns, R.
    Scheele, J.
    Straub, J.
    Paik, P.
    ANNALS OF ONCOLOGY, 2018, 29 : 152 - 152
  • [32] Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
    Ahn, Linda
    Alexander, Terri
    Vlassak, Soetkin
    Berghoff, Karin
    Lemmens, Liesbeth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (05) : 543 - 551
  • [33] Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features
    Meng, Yan
    Zhou, Weiping
    Li, Chenping
    Zhou, Xiangjie
    Li, Xiao
    Li, Liang
    Fu, Qiye
    Huang, Jue
    Yue, Yali
    Shen, Xuguang
    Yang, Lijing
    Wang, Meiqing
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [34] Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping.
    Le, Xiuning
    Felip, Enriqueta
    Veillon, Remi
    Sakai, Hiroshi
    Cortot, Alexis B.
    Garassino, Marina Chiara
    Mazieres, Julien
    Ramirez, Santiago Viteri
    Senellart, Helene
    Van Meerbeeck, Jan
    Reinmuth, Niels
    Conte, Pier Franco
    Kowalski, Dariusz
    Cho, Byoung Chul
    Straub, Josef
    Scheele, Jurgen
    Juraeva, Dilafruz
    Bruns, Rolf
    Heymach, John
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Tepotinib Treatment of Patients with Skipping Mutation in Exon 14 of the MET-Gene (METex14) in non-small cell Lung Cancer: Interim Analysis of VISION Cohorts A (Primary Analysis) and C (confirmatory Analysis)
    Wermke, M.
    Griesinger, F.
    Thomas, M.
    Reinmuth, N.
    Overbeck, T.
    Alt, J.
    Henschke, S.
    Wehler, T.
    Ochsenreither, S.
    Garassino, M. C.
    Felip, E.
    Sakai, H.
    Bruns, R.
    Otto, G.
    Johne, A.
    Paik, P. K.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 54 - 55
  • [36] Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal or bone metastases in the phase II VISION trial
    Gasking, Stephanie
    Reinmuth, Niels
    Mazieres, Julien
    Popat, Sanjay
    Paz-Ares, Luis
    Hook, Emma
    Hatswell, Anthony
    Vlassak, Soetkin
    Johne, Andreas
    Vioix, Helene
    Paik, Paul
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 : 132 - 133
  • [37] Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
    Yang, Mo
    Vioix, Helene
    Hook, Emma S.
    Hatswell, Anthony J.
    Batteson, Rachael L.
    Gaumond, Bruce R.
    O'Brate, Aurora
    Popat, Sanjay
    Paik, Paul K.
    VALUE IN HEALTH, 2023, 26 (08) : 1155 - 1163
  • [38] Health-related quality of life (HRQoL) with tepotinib in patients with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC) with brain, liver, adrenal, or bone metastases in the phase II VISION trial.
    Reinmuth, Niels
    Mazieres, Julien
    Popat, Sanjay
    Paz-Ares, Luis G.
    Hook, Emma S.
    Hatswell, Anthony
    Vlassak, Soetkin
    Johne, Andreas
    Vioix, Helene
    Paik, Paul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [39] Brain metastases (BM) and next-generation sequencing (NGS) timing: Real-world (RW) outcomes for patients (pts) with advanced non-small cell lung cancer (aNSCLC) and MET exon 14 skipping mutations (METex14)
    Le, Xiuning
    Robb, Stephen
    Caro, Nydia
    Doria, Simona
    Rhodes, Whitney C.
    Wu, Wen-Hsing
    Kim, Julia
    Pretre, Vincent
    Ye, Fen
    CANCER RESEARCH, 2022, 82 (12)
  • [40] Genomic comparison of MET exon 14 skipping and MET amplified non-small cell lung cancer.
    Minne, Rachel
    Luo, Natalie
    Traynor, Anne M.
    Huang, Minxuan
    De Tullio, Luisina
    Godden, Jen
    Stoppler, Melissa Conrad
    Kimple, Randall J.
    Baschnagel, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345